Compare Merck & Co., Inc. (MRK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: Merck & Co., Inc. is far larger — about 7.4× iShares 20 Plus Year Treasury Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| MRK | TLT | |
|---|---|---|
Market Cap | $351.28B | $47.61B |
Volume | 7,969,665 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $92.06 |
52-Week Low | $82.49 | $77.11 |
Typical Hold Time | 98 Days | 83 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.87, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators remain neutral. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds as investors face elevated interest rate expectations.
The ETF faces significant interest rate risk with the Federal Reserve maintaining higher rates. Current yields above 5% offer attractive income but price depreciation remains a concern. Key risks include prolonged high inflation, further Fed tightening, and economic growth surprises that could extend the bond market downturn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
